- (PLX AI) - Genmab shares rose more than 2% after the FDA issued accelerated approval for TIVDAK, a treatment for cervical cancer.
- • The approval was widely expected in the market
- • It's a relatively small opportunity for Genmab, but it is the first therapy the company is co-promoting itself, so it's important for Genmab's long-term ambitions to become a fully-fledged biopharma company, SEB said